natgillin/translations-raw huggingface dataset:
Budesonide is excreted in human milk (data on excretion after inhalative use is available). 
Budezonid se izloča v materino mleko (na voljo so podatki o izločanju pri inhalacijski uporabi), vendar po peroralni uporabi terapevtskih odmerkov zdravila Jorveza pri dojenih otrocih pričakujemo le manjše učinke.
Swallow the dissolved material with saliva little by little, as the orodispersible tablet breaks up. 
Medtem ko orodisperzibilna tableta razpada, raztopljeni material postopno požirajte s slino.
Blood cortisol decreased 
Preiskave znižanje ravni kortizola v krvi
Muscle and joint pain, muscle weakness and twitching, osteoporosis, osteonecrosis 
Pri bolnikih s tuberkulozo, hipertenzijo, sladkorno boleznijo, osteoporozo, peptičnim ulkusom,
Dyspepsia, duodenal or gastric ulcers, pancreatitis, constipation 
Bolezni prebavil dispepsija, razjeda dvanajstnika ali želodca, pankreatitis, zaprtje
Administration during pregnancy should be avoided unless there are compelling reasons for therapy with Jorveza. 
Če zdravljenje z zdravilom Jorveza ni res nujno, se morate njegovi uporabi v času nosečnosti izogibati, saj je na voljo le malo podatkov o izidu nosečnosti pri človeku po peroralni uporabi budezonida.
The following known adverse reactions of the therapeutic class (corticosteroids, budesonide) could also occur with Jorveza (frequency = not known). 
(kortikosteroidi, budezonid) (pogostnost = neznana).
Sodium hydrogen carbonate Sucralose 
Žilne bolezni hipertenzija
Strength Pharmaceutical Form Route of Administration Packaging 
ime jakost farmacevtska oblika pot uporabe ovojnina velikost pakiranja o ā
- if you have cancer. 
- če imate raka.
EXP After first opening, use within 30 days. 
EXP Po prvem odprtju porabite v 30 dneh.
That parents and caregivers should always ensure that the child has a source of sugar. 
Da morajo starši in skrbniki vedno zagotoviti, da ima otrok vir sladkorja.
• Long-term toxicity in patients undergoing developmental changes 
• dolgotrajno toksičnost pri bolnikih, ki so podvrženi razvojnim spremembam,
- if you have finished growing (the bone growth plates are closed). 
- če ste nehali rasti (rastne plošče kosti so zaprte).
Date of latest renewal: 03 August 2017 
Datum zadnjega podaljšanja: 03. avgust 2017
Efficacy is dose dependent. 
Učinkovitost je odvisna od odmerka.
Treatment success should be evaluated based on height velocities. 
Uspeh zdravljenja je treba ovrednotiti na osnovi hitrosti rasti.
These studies did not indicate direct or indirect harmful effects with respect to fertility and pregnancy, but due to the different route of application the relevance of these findings is unclear. 
Te študije niso pokazale neposrednih ali posrednih škodljivih učinkov na plodnost in nosečnost, vendar pa zaradi drugačne poti uporabe ustreznost teh ugotovitev ni jasna.
Store in a refrigerator (2C - 8°C). 
Shranjujte v hladilniku (2 C - 8 °C).
Worsened scoliosis (caused by rapid growth) 
Poslabšanje skolioze (zaradi hitre rasti)
MARKETING AUTHORISATION NUMBER(S) EU/1/07/402/001 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/07/402/001
This medicinal product should not be used during pregnancy unless clearly necessary. 
Tega zdravila ne smete uporabljati med nosečnostjo, razen če je nujno potrebno.
Some patients required hospitalization. 
Nekateri bolniki so potrebovali zdravljenje v bolnišnici.
Upon re-administration, symptoms did not re-occur in all patients. 
Po ponovni uvedbi zdravljenja se simptomi niso ponovili pri vseh bolnikih.
The safety and efficacy of mecasermin in children below age of 2 have not been established (see section 5.1). 
Varnost in učinkovitost mekazermina pri otrocih, mlajših od 2 let, nista bili dokazani (glejte poglavje 5.1).
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 03 August 2007 
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Z ZDRAVILOM Datum prve odobritve: 03. avgust 2007
You are now ready to inject (see Figure 7). 
Sedaj ste pripravljeni na injiciranje (glejte sliko 7).
It is important that you have a well-balanced diet including protein and fat such as meat and cheese in addition to sugarcontaining foods. 
Pomembno je, da imate dobro uravnoteženo prehrano, ki poleg hranil s sladkorjem vključuje tudi beljakovine in maščobe, npr. meso in sir.
Long-term overdose may result in enlargement of certain body parts (e.g., hands, feet, parts of the face) or excessive growth of the whole body. 
Zaradi dolgotrajnega prevelikega odmerjanja se lahko povečajo nekateri deli telesa (npr. roke, noge, deli obraza) ali pojavi prekomerna rast celega telesa.
Systemic/local hypersensitivity 
Sistemska/lokalna preobčutljivost
• basal IGF-1 levels below the 2.5th percentile for age and gender and 
• osnovna raven IGF-1, manjša od 2,5. percentila, glede na starost in spol in
• GH sufficiency. 
• zadostna količina GH.
Injecting the dose: 
Injiciranje odmerka:
This condition is called primary IGF-1 deficiency. 
To stanje imenujemo primarno pomanjkanje IGF-1.
Use syringes and needles only once. 
Brizgo in iglo uporabite le enkrat.
To perform one long-term safety study where mecasermin treatment is initiated in early phase of childhood and continued to adulthood in order to investigate: 
Izvajanje dolgoročne varnostne študije, kjer se je zdravljenje z mekazerminom začelo v zgodnjem otroštvu in se nadaljuje v odraslem obdobju, da bi bilo mogoče raziskati:
Uncommon: Depression, nervousness 
Občasni: depresija, živčnost
- in premature babies or neonates because it contains benzyl alcohol. 
- pri nedonošenčkih ali novorojenčkih, ker zdravilo vsebuje benzilalkohol.
Check the liquid to make sure it is clear and colourless. 
Preverite tekočino in se prepričajte, da je bistra in brezbarvna.
This medicine has been authorised under ‘exceptional circumstances'. 
Zdravilo je pridobilo dovoljenje za promet v “izjemnih okoliščinah”.
Among all subjects included for safety evaluation (n=92), 83% of the subjects reported at least one adverse event during the course of the studies. 
Med vsemi osebami, vključenimi v vrednotenje varnosti (n=92), so pri 83 % oseb poročali o pojavu vsaj enega neželenega učinka med potekom študij.
Never inject it into a vein or muscle. 
Zdravila ne smete nikoli injicirati v žilo ali mišico.
Sleep apnea can cause excessive daytime sleepiness. 
Apneja v spanju lahko povzroči prekomerno zaspanost podnevi.
All cases were mild or moderate in severity and none was serious. 
Vsi primeri so bili blagi ali zmerni.
• INCRELEX should not be administered if the patient is unable to eat for any reason. 
• Zdravila INCRELEX ni dovoljeno dajati, če bolnik zaradi kakršnegakoli razloga ne more jesti.
Lonza AG Lonzastrasse CH-3930 Visp Switzerland 
Lonza AG Lonzastrasse CH-3930 Visp Švica
Beaufour Ipsen Industrie Rue d'Ethe Virton 28100 Dreux France 
Beaufour Ipsen Industrie Rue d'Ethe Virton 28100 Dreux Francija
Do not use INCRELEX - if you are allergic to mecasermin or any of the other ingredients of this medicine (listed in section 6). 
Ne uporabljajte zdravila INCRELEX - če ste alergični na mekazermin ali katerokoli sestavino tega zdravila (navedeno v poglavju 6).
Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency (not known). 
Ker so bila ta poročila pridobljena spontano iz populacije bolnikov neznane velikosti, njihove pogostnosti ni mogoče zanesljivo oceniti (neznana pogostnost).
- It is used to treat children and adolescents from 2 to 18 years old who are very short for their age because their bodies do not make enough IGF-1. 
- Uporabljamo ga za zdravljenje otrok in mladostnikov, starih od 2 do 18 let, ki so za svojo starost zelo nizke rasti, ker njihova telesa ne proizvajajo dovolj IGF-1.
Mecasermin should not be used for growth promotion in patients with closed epiphyses. 
Mekazermina se ne sme uporabljati za pospeševanje rasti pri bolnikih z zaprtimi epifizami.
Race No information is available. 
Rasa Podatki niso na voljo.
Baseline characteristics for the 81 patients evaluated in the primary and secondary efficacy analyses from the combined studies were (mean ± SD): chronological age (years): 6.8  3.8; age range (years): 1.7 to 17.5; height (cm): 84.1  15.8; height standard deviation score (SDS): -6.9  1.8; height velocity (cm/yr): 2.6  1.7; height velocity SDS: -3.4  1.6; IGF-1 (ng/ml): 24.5  27.9; IGF-1 SDS: -4.2  2.0; and bone age (years): 3.8  2.8. 
Izhodiščne lastnosti 81 bolnikov, ki so jih vrednotili pri primarnih in sekundarnih analizah učinkovitosti kombiniranih študij, so bile (povprečna vrednost ± SD): kronološka starost (leta): 6,8  3,8; starostni razpon (leta): 1,7 do 17,5; telesna višina (cm): 84,1  15,8; vrednost standardnega odklona (Standard deviation score - SDS) telesne višine: -6,9  1,8; hitrost rasti (cm/leto): 2,6  1,7; SDS hitrosti rasti: -3,4  1,6; IGF-1 (ng/ml): 24,5  27,9; SDS IGF-1: -4,2  2,0; in zrelost kosti (leta): 3,8  2,8.
There was no death during the studies. 
V času študij smrtnih primerov ni bilo.
Doses of insulin and/or other hypoglycaemic medicinal products may need to be reduced (see section 4.4). 
Odmerke insulina in/ali drugih hipoglikemičnih zdravil bo morda treba zmanjšati (glejte poglavje 4.4).
Severe Primary IGFD is defined by: 
Hudo primarno pomanjkanje IGF je definirano kot:
• height standard deviation score  -3.0 and 
• vrednost standardnega odklona (SDS) telesne višine  -3,0 in
In some cases, when deemed necessary, the physician may decide to assist in the diagnosis by performing an IGF-I generation test. 
V nekaterih primerih, kadar je to potrebno, si lahko zdravnik pri diagnosticiranju pomaga z izvedbo testa IGF-1.
Figure 1: Wipe top with alcohol 
Slika 1: Vrh obrišite z alkoholom
For further information ask the doctor. 
Za nadaljnje informacije se obrnite na zdravnika.
Table 1 contains very common (≥ 1/10), common (≥ 1/100 to < 1/10) and uncommon (≥ 1/1000, < 1/100) adverse reactions which occurred in clinical trials. 
V preglednici 1 so navedeni zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10) in občasni (≥ 1/1.000 do < 1/100) neželeni učinki, ki so se pojavili med kliničnimi preskušanji.
• Physician information about INCRELEX (information card, dosing guide, and a dose calculator) 
• Informacije za zdravnika o zdravilu INCRELEX (informacijsko kartico, navodilo za odmerjanje in kalkulator odmerkov)
Table 2: Annual Height Results by Number of Years Treated with INCRELEX Pre-Tx Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7 Year 8 
Preglednica 2: Letni rezultati telesne višine glede na število let zdravljenja z zdravilom INCRELEX Pre-Tx Leto 1 Leto 2 Leto 3 Leto 4 Leto 5 Leto 6 Leto 7 Leto 8
Mecasermin is not a substitute for GH treatment. 
Mekazermin ni nadomestilo za zdravljenje z GH.
Annual results for height velocity, height velocity SDS, and height SDS until year 8 are shown in Table 2. 
Letni rezultati o hitrost rasti, SDS hitrosti rasti in SDS telesne višine do 8. leta so prikazani v preglednici 2.
IGF-1 has mitogenic activity that leads to an increased number of cells in the body. 
IGF-1 deluje mitogeno, kar vodi k povečanju števila celic v telesu.
Lightly pinch the skin. 
Kožo rahlo stisnite v gubo.
The dose should be individualised for each patient. 
Odmerek je treba prilagoditi vsakemu bolniku posebej.
Frequency not known (frequency cannot be estimated from the available data) Serious allergic reactions (anaphylaxis) 
Neželeni učinki neznane pogostnosti (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti) Resne alergijske reakcije (anafilaksija)
This medicinal product contains less than 1 mmol sodium (23 mg) per vial, i.e. essentially ‘sodium-free'. 
To zdravilo vsebuje manj kot 1 mmol (23 mg) natrija na vialo, kar v bistvu pomeni “brez natrija”.
Adverse reactions not observed in clinical studies, but seen in animals at exposure levels similar to clinical exposure levels and with possible relevance to clinical use were as follows: 
Neželeni učinki, ki jih v kliničnih študijah niso opazili, v študijah na živalih pa so jih opazili pri stopnjah izpostavljenosti, ki so bile podobne stopnjam klinične izpostavljenosti, in bi lahko bili klinično pomembni, so naslednji:
Do not rub the area (see Figure B). 
Mesta ne drgnite (glejte sliko B).
If hypoglycaemia occurs with recommended doses, despite adequate food intake, the dose should be reduced. 
Če se pri uporabi priporočenih odmerkov kljub zadostnemu vnosu hrane pojavi hipoglikemija, je treba odmerek zmanjšati.
Your doctor can check to see if intracranial hypertension is present. 
Zdravnik bo med pregledom preveril, če se je pojavila intrakranialna hipertenzija.
Slowly push in the plunger of the syringe all the way, making sure you have injected all the liquid. 
Počasi pritiskajte na bat brizge do konca in se prepričajte, da ste injicirali vso tekočino.
In such instances, instructions for antibody testing should be considered. 
V tovrstnih primerih je treba razmisliti o testiranju protiteles.
Figure B: Press (don't rub) with gauze or cotton 
Slika B: Pritisnite (ne drgnite) z gazo ali vato
• The signs and symptoms of hypoglycaemia. 
• Znaki in simptomi hipoglikemije.
SPECIFIC OBLIGATION TO COMPLETE POST-AUTHORISATION MEASURES FOR THE MARKETING AUTHORISATION UNDER EXCEPTIONAL CIRCUMSTANCES This being an approval under exceptional circumstances and pursuant to Article 14(8) of Regulation (EC) No 726/2004, the MAH shall conduct, within the stated timeframe, the following measures: 
DOVOLJENJA ZA PROMET Z ZDRAVILOM V IZJEMNIH OKOLIŠČINAH Ker gre za odobritev v izjemnih okoliščinah in ob upoštevanju člena 14(8) Uredbe (ES) št. 726/2004, mora imetnik dovoljenja za promet v določenem časovnem okviru izvesti naslednje ukrepe: Opis
If the patient is unable to eat, for any reason, this medicinal product should be withheld. 
Če bolnik zaradi kateregakoli razloga ne more jesti, je treba zdravljenje s tem zdravilom začasno prekiniti.
Preparing the dose 
Priprava odmerka
Long-term overdose may result in signs and symptoms of acromegaly or gigantism. 
Zaradi dolgotrajnega prevelikega odmerjanja se lahko pojavijo znaki in simptomi akromegalije ali gigantizma.
Figure 6: Remove air bubbles and refill syringe 
Slika 6: Odstranite zračne mehurčke in znova napolnite brizgo
• Exclusion of secondary forms of IGF-1 deficiency, such as malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids. 
• Izključitev sekundarnih oblik pomanjkanja IGF-1, kot so podhranjenost, hipotiroidizem ali kronično zdravljenje s farmakološkimi odmerki kortikosteroidov.
INCRELEX may have a major influence on the ability to drive or use machines in case of a hypoglycaemic episode. 
Zdravilo INCRELEX ima lahko pomemben vpliv na sposobnost vožnje ali upravljanja strojev v primeru pojava hipoglikemije.
No attenuation of growth was observed as a consequence of the development of antibodies. 
Upočasnitve rasti kot posledice tvorbe protiteles niso opazili.
Reactions at the injection site 
Reakcije na mestu injiciranja
• Instructions to report the onset or worsening of snoring that may indicate an increase in growth of tonsils and/or adenoids following the beginning of treatment with INCRELEX. 
• Navodila za poročanje o pojavu ali poslabšanju smrčanja, kar lahko nakazuje povečano rast tonzil in/ali adenoidnega tkiva kot posledico začetka zdravljenja z zdravilom INCRELEX.
Never share needles and syringes. 
Igel in brizg ne smete nikoli deliti z drugimi.
Your doctor may perform an echocardiogram before, during and after mecasermin treatment. 
Zdravnik lahko ehokardiogram izvede pred, med in po zdravljenju z mekazerminom.
In addition there will be a dosing guide, and a dose calculator, for use by physician and patients to include information on the individualised dose escalation to minimise the risk of medication errors and hypoglycaemia. 
Dodatno bodo na voljo navodila za odmerjanje in kalkulator odmerkov za zdravnike in bolnike, ki vključujejo podatke za prilagoditev odmerka za posameznega bolnika z namenom zmanjšanja tveganja napak pri zdravljenju in hipoglikemije.
Precaution to be taken before manipulating or administering the medicinal product The solution should be clear immediately after removal from the refrigerator. 
Previdnostni ukrepi, potrebni pred ravnanjem z zdravilom ali dajanjem zdravila Raztopina mora biti bistra takoj, ko jo vzamete iz hladilnika.
• Instructions to change and rotate the site of injection for each injection to avoid the development of lipohypertrophy. 
• Navodila za spreminjanje in menjavanje vbodnega mesta za vsako injekcijo, z namenom izogiba razvoja lipohipertrofije.
Figure 7: Ready to inject 
Slika 7: Brizga pripravljena za injiciranje
Special attention should be paid to young children, children with a history of hypoglycaemia and children with inconsistent food intake. 
Posebna pozornost je potrebna pri majhnih otrocih, otrocih s hipoglikemijo v anamnezi in otrocih z nerednim prehranjevanjem.
The bioavailability of mecasermin after subcutaneous administration in healthy subjects has been reported to be approximately 100%. 
Biološka uporabnost mekazermina po subkutanem dajanju zdravim osebam je glede na poročila približno 100-odstotna.
A dose adjustment may be needed for these medicines. 
Zdravnik bo odmerek teh zdravil morda moral prilagoditi.
Uncommon: Benign intracranial hypertension 
Občasni: benigna intrakranialna hipertenzija
Before beginning treatment with INCRELEX the doctor or nurse will explain to you how to treat hypoglycaemia. 
Pred začetkom zdravljenja z zdravilom INCRELEX vam bosta zdravnik ali medicinska sestra razložila, kako ukrepati v primeru hipoglikemije.
Cell growth: IGF-1 receptors are present on most types of cells and tissues. 
Celična rast: receptorji za IGF-1 se nahajajo na večini vrst celic in v večini tkiv.
Breast-feeding while taking INCRELEX is not recommended, because there is insufficient information on the excretion of mecasermin in human milk. 
Med zdravljenjem z zdravilom INCRELEX dojenje ni priporočljivo, saj ni dovolj podatkov o izločanju mekazermina v materino mleko.
Skeletal growth is accomplished at the epiphyseal plates at the ends of a growing bone. 
Rast okostja, ki se odvija na področju epifiznih plošč na konceh rastoče kosti.
The height velocities for years 2 through 8 remained statistically greater than baseline. 
Hitrost rasti od 2. do 8. leta je ostala statistično večja v primerjavi z izhodiščem.
Active or suspected neoplasia. 
Aktivna neoplazija ali sum nanjo.
Patients with abnormal echocardiogram findings or cardiovascular symptoms should be followed regularly with echocardiogram procedures. 
Bolnike z nenormalnim izvidom ali bolnike s kardiovaskularnimi simptomi je treba redno spremljati z ehokardiogramom.
• To perform a routine funduscopic examination prior to beginning treatment and periodically during treatment or at the occurrence of clinical symptoms. 
• Izvesti rutinski fundoskopski pregled pred začetkom zdravljenja in redno med terapijo ali pri pojavu kliničnih simptomov.
If the solution is cloudy, or contains particulate matter, it must not be injected. 
Če je raztopina motna ali vsebuje delce, je ne smete injicirati.
Under normal circumstances, growth hormone (GH) binds to its receptor in the liver and other tissues, and stimulates the synthesis/secretion of IGF-1. 
V običajnih pogojih se rastni hormon (GH) veže na odgovarjajoče receptorje v jetrih in drugih tkivih ter spodbuja sintezo/izločanje IGF-1.
Figure A: Lightly pinch the skin and inject as instructed 
Slika A: Kožo rahlo stisnite v gubo in injicirajte kot vam je pokazal zdravnik
Reactions observed in the clinical trials 
Neželeni učinki, opaženi v kliničnih preskušanjih
Especially tell the doctor if you take insulin or other anti-diabetes medicines. 
Zdravnika še posebej obvestite, če se zdravite z insulinom ali drugimi zdravili za zdravljenje sladkorne bolezni.
Severe Primary IGFD includes patients with mutations in the GH receptor (GHR), post-GHR signaling pathway, and IGF-1 gene defects; they are not GH deficient, and therefore, they cannot be expected to respond adequately to exogenous GH treatment. 
Hudo primarno pomanjkanje IGF vključuje bolnike z mutacijami receptorjev za GH (GHR), post-GHR signalnih poti in okvar gena za IGF-1; pri teh bolnikih ne gre za pomanjkanje GH in zato ne moremo pričakovati, da se bodo zadostno odzvali na zdravljenje z eksogenim GH.
INFORMATION IN BRAILLE INCRELEX 
PODATKI V BRAILLOVI PISAVI INCRELEX
Slough, Berkshire SL1 3XE 
190 Bath Road Slough, Berkshire SL1 3XE
IH-associated signs and symptoms resolved after interruption of dosing. 
Znaki in simptomi, povezani z IH, so po prekinitvi zdravljenja minili.
If a vial freezes, dispose appropriately. 
Če viala zmrzne, jo ustrezno zavrzite.
For the long-term treatment of growth failure in children and adolescents from 2 to 18 years with severe primary insulin-like growth factor-1 deficiency (Primary IGFD). 
Dolgotrajno zdravljenje zaostajanja v rasti pri otrocih in mladostnikih, starih od 2 do 18 let, s hudim primarnim pomanjkanjem insulinu podobnega rastnega faktorja-1 (primarno pomanjkanje IGF).
If a person with severe hypoglycemia is unconscious or otherwise unable to ingest food normally, an injection of glucagon may be required. 
Če je oseba s hudo hipoglikemijo nezavestna ali kako drugače nezmožna na običajen način zaužiti hrano, bo morda potrebna injekcija glukagona.
Treatment with mecasermin should be directed by physicians who are experienced in the diagnosis and management of patients with growth disorders. 
Zdravljenje z mekazerminom mora voditi zdravnik, ki ima izkušnje z diagnosticiranjem in zdravljenjem bolnikov z motnjami rasti.
If the recommended dose is not tolerated by the patient, treatment with a lower dose can be considered. 
Če bolnik priporočenega odmerka ne prenaša, je potrebno presoditi o zdravljenju z nižjim odmerkom.
A disruption or early ending of treatment with mecasermin may impair the success of the growth therapy. 
Posledica vmesnih prekinitev ali prezgodnje dokončne ukinitve zdravljenja z mekazerminom je lahko neuspešno zdravljenje zavrte rasti.
Figure 5: Extract correct dose 
Slika 5: Izvlecite ustrezen odmerek
For the 21 treatment naïve subjects with near-adult height, the mean (± SD) of the difference between observed increase in height versus that expected from Laron was approximately 13 cm (± 8 cm) after an average of 11 years of treatment. 
Pri 21 predhodno nezdravljenih osebah s skoraj odraslo telesno višino je povprečna (± SD) razlika med opaženim povečanjem telesne višine v primerjavi s pričakovano po Laronu v povprečju po 11 letih zdravljenja znašala približno 13 cm (± 8 cm).
Benzyl alcohol may cause toxic reactions and anaphylactoid reactions in infants and children up to 3 years old. 
Benzilalkohol lahko povzroči toksične in anafilaktoidne reakcije pri dojenčkih in otrocih do 3. leta starosti.
Insulin-like growth factor-1 (IGF-1) is the principal hormonal mediator of statural growth. 
Insulinu podoben rastni faktor-1 (IGF-1) je glavni hormonski posrednik telesne rasti.
Leave the syringe in the vial and turn both upside down. 
Brizgo pustite v viali in nato obe skupaj obrnite na glavo.
The physician information about INCRELEX should contain the following key elements: 
Informacije za zdravnika o zdravilu INCRELEX morajo vsebovati naslednje ključne elemente:
The use of this medicine has not been studied in children under 2 years of age and is therefore not recommended. 
Uporabe tega zdravila pri otrocih, mlajših od 2 let, niso raziskovali, zato pri njih uporaba tega zdravila ni priporočljiva.
Other medicines and INCRELEX 
Druga zdravila in zdravilo INCRELEX
• INCRELEX is contraindicated in the presence of active or suspected neoplasia, and therapy should be discontinued if evidence of neoplasia develops. 
• Zdravilo INCRELEX je kontraindicirano ob prisotnosti aktivne neoplazije ali suma nanjo, zato je treba zdravljenje prekiniti, če se razvije dokazljiva neoplazija.
You should be monitored for progression of scoliosis. 
Napredovanje skolioze je treba nadzirati.
Instructions on the treatment of hypoglycaemia. 
Navodila za zdravljenje hipoglikemije.